CAMBRIDGE

(City)

(Last)

MA

(State)

(First)

1. Name and Address of Reporting Person* **GADICKE ANSBERT**

C/O MPM ASSET MANAGEMENT

450 KENDALL STREET

02142

(Zip)

(Middle)

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden

0.5

				SECURITIES			hours pe	r response: 0.5
				n 16(a) of the Securities Exchange of the Investment Company Act of 2				
1. Name and Address of Reporting Person* MPM BIOVENTURES V, L.P. 2. Date of Event Requiring Statement (Month/Day/Year) 10/04/2017			3. Issuer Name and Ticker or Trading Symbol RHYTHM PHARMACEUTICALS, INC. [RYTM]					
(Last) (First) (Middle) C/O MPM ASSET MANAGEMENT 450 KENDALL STREET				4. Relationship of Reporting Per (Check all applicable) Director Officer (give title below)	. ,	(Mor	nth/Day/Year)	ate of Original Filed t/Group Filing (Check
(Street) CAMBRIDGE MA 02142 (City) (State) (Zip)						X	Form filed b	by One Reporting Person by More than One Person
(Out) (Out) (E.P)		Table I - No	n-Deriva	 ative Securities Beneficia	llv Owned			
1. Title of Security (Instr. 4)				2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownersh Form: Direct or Indirect (Instr. 5)	t (D) (Instr		t Beneficial Ownership
Common Stock				29,378(1)	I	See I	Footnote ⁽²⁾	
	(e.			ve Securities Beneficially rants, options, convertibl		s)		
1. Title of Derivative Security (Instr. 4)		2. Date Exercisable and Expiration Date (Month/Day/Year)			and Amount of Securities ing Derivative Security (Instr. 4)		5. Ownership Form:	6. Nature of Indirect Beneficial Ownership (Instr. 5)
		Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Price of Derivative Security	Direct (D) or Indirect (I) (Instr. 5)	
Series A Preferred Stock		(3)	(3)	Common Stock	834,441	(3)	I	See Footnote ⁽⁴⁾
Series A-1 Junior Preferred Stock		(3)	(3)	Common Stock	1,732,573	(3)	I	See Footnote ⁽⁵⁾
1. Name and Address of Reporting Person* MPM BIOVENTURES V, L.P.								
(Last) (First) C/O MPM ASSET MANAGEMENT 450 KENDALL STREET	(Middle	?)	_					
(Street) CAMBRIDGE MA	02142	!						
(City) (State)	(Zip)							
1. Name and Address of Reporting Person* EVNIN LUKE								
(Last) (First) C/O MPM ASSET MANAGEMENT 450 KENDALL STREET	(Middle	2)						
(Street)								

CAMBRIDGE	MA	02142					
(City)	(State)	(Zip)					
1. Name and Address of Reporting Person* MPM ASSET MANAGEMENT INVESTORS BV5 LLC							
(Last)	(First)	(Middle)					
C/O MPM ASSET MANAGMENT							
450 KENDALL STREET							
(Street) CAMBRIDGE	MA	02142					
(City)	(State)	(Zip)					
1. Name and Address of Reporting Person* MPM BIOVENTURES V GP LLC							
(Last)	(First)	(Middle)					
C/O MPM ASSET	MANAGEMENT						
450 KENDALL ST	FREET						
(Street) CAMBRIDGE	MA	02142					
(City)	(State)	(Zip)					
1. Name and Address of Reporting Person* MPM BIOVENTURES V LLC							
(Last)	(First)	(Middle)					
C/O MPM ASSET MANAGEMENT							
450 KENDALL STREET							
(Street) CAMBRIDGE	MA	02142					
(City)	(State)	(Zip)					

Explanation of Responses:

- 1. Reflects a 1-for-9.17 reverse split effective as of September 29, 2017.
- 2. The shares are held as follows: 28,280 by MPM BioVentures V, L.P. ("BV V") and 1,098 by MPM Asset Management Investors BV5 LLC ("AM BV5"). MPM BioVentures V GP LLC and MPM Bio Ventures V LLC ("BV LLC") are the direct and indirect general partners of BV V and BV LLC is the manager of AM BV5. Ansbert Gadicke, Luke Evnin and Todd Foley are the members of BV LLC. Mr. Foley is a director of the Issuer and has separately filed a Form 3. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
- 3. Each share of Series A Preferred Stock and Series A-1 Junior Preferred Stock is convertible into 0.10905125 of a share of Common Stock without payment of further consideration and will automatically convert into 0.10905125 of a share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.
- 4. The shares are held as follows: 803,237 by BV V and 31,204 by AM BV5. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary
- 5. The shares are held as follows: 1,667,782 by BV V and 64,791 by AM BV5. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.

Remarks:

(Street)

By Luke Evnin, member of MPM BioVentures V LLC, the managing member of MPM BioVentures V GP LLC, the 10/04/2017 general partner of MPM BioVentures V, L.P. /s/ Luke /s/ Luke Evnin 10/04/2017 /s/ Ansbert Gadicke 10/04/2017 By Luke Evnin, member of MPM BioVentures V LLC, the manager of MPM Asset 10/04/2017 Management Investors BV5 LLC /s/ Luke Evnin By Luke Evnin, member of MPM BioVentures V LLC, the managing member of MPM 10/04/2017 BioVentures V GP LLC /s/ Luke Evnin

By Luke Evnin, member of MPM BioVentures V LLC /s/ Luke Evnin

** Signature of Reporting Person

Date

10/04/2017

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.